Clinical Trial Detail

NCT ID NCT02238522
Title Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Zenith Epigenetics Corp.
Indications

acute myeloid leukemia

Therapies
Age Groups: adult

No variant requirements are available.